Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 29.71% and Operating profit at -291.25% over the last 5 years
3
With a growth in Operating Profit of 141.72%, the company declared Outstanding results in Sep 25
4
With ROE of -2.90%, it has a risky valuation with a 8.39 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,232 Million (Large Cap)
109.00
NA
0.20%
0.01
3.77%
4.73
Revenue and Profits:
Net Sales:
257 Million
(Quarterly Results - Mar 2026)
Net Profit:
28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.21%
0%
-7.21%
6 Months
-4.13%
0%
-4.13%
1 Year
-16.93%
0%
-16.93%
2 Years
65.22%
0%
65.22%
3 Years
43.53%
0%
43.53%
4 Years
14.3%
0%
14.3%
5 Years
-24.94%
0%
-24.94%
Shenzhen Chipscreen Biosciences Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
26.40%
EBIT Growth (5y)
63.15%
EBIT to Interest (avg)
-1.20
Debt to EBITDA (avg)
0.92
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.23
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
46.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.03%
ROE (avg)
1.36%
Valuation key factors
Factor
Value
P/E Ratio
109
Industry P/E
Price to Book Value
4.10
EV to EBIT
78.77
EV to EBITDA
56.03
EV to Capital Employed
4.07
EV to Sales
10.58
PEG Ratio
0.59
Dividend Yield
0.22%
ROCE (Latest)
5.17%
ROE (Latest)
3.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
257.00
160.30
60.32%
Operating Profit (PBDIT) excl Other Income
38.80
4.20
823.81%
Interest
8.50
9.90
-14.14%
Exceptional Items
0.80
0.00
Consolidate Net Profit
28.30
-19.20
247.40%
Operating Profit Margin (Excl OI)
150.80%
-86.50%
23.73%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 60.32% vs 22.74% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 247.40% vs -4.92% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
907.50
655.80
38.38%
Operating Profit (PBDIT) excl Other Income
155.30
0.90
17,155.56%
Interest
35.80
34.40
4.07%
Exceptional Items
0.20
-90.00
100.22%
Consolidate Net Profit
51.00
-114.60
144.50%
Operating Profit Margin (Excl OI)
90.80%
-92.40%
18.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 38.38% vs 27.14% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 144.50% vs -332.93% in Dec 2024
About Shenzhen Chipscreen Biosciences Co., Ltd. 
Shenzhen Chipscreen Biosciences Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






